Product
GH001
Aliases
5-MeO-DMT, 5-Methoxy-N,N-Dimethyltryptamine, Mebufotenin
3 clinical trials
3 indications
Indication
Bipolar II DisorderIndication
Postpartum DepressionIndication
DepressionClinical trial
A Phase 2 Clinical Trial of GH001 in Patients With Bipolar II Disorder and a Current Major Depressive EpisodeStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 2 Clinical Trial of GH001 in Patients With Postpartum DepressionStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2b Trial With an Open-label Extension to Determine the Safety and Efficacy of GH001 in Patients With Treatment-resistant DepressionStatus: Recruiting, Estimated PCD: 2024-06-01